Charles Schwab Investment Management Inc. Has $860.29 Million Position in Danaher Co. (NYSE:DHR)

Charles Schwab Investment Management Inc. boosted its holdings in Danaher Co. (NYSE:DHR) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,718,735 shares of the conglomerate’s stock after purchasing an additional 95,440 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.50% of Danaher worth $860,292,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Everhart Financial Group Inc. bought a new position in shares of Danaher in the third quarter valued at approximately $327,000. BluePath Capital Management LLC bought a new stake in Danaher in the 3rd quarter worth about $44,000. Pinnacle Wealth Management Advisory Group LLC grew its position in Danaher by 25.0% in the 3rd quarter. Pinnacle Wealth Management Advisory Group LLC now owns 2,117 shares of the conglomerate’s stock worth $525,000 after purchasing an additional 424 shares in the last quarter. Calamos Advisors LLC grew its position in Danaher by 8.4% in the 3rd quarter. Calamos Advisors LLC now owns 242,244 shares of the conglomerate’s stock worth $60,101,000 after purchasing an additional 18,776 shares in the last quarter. Finally, First Merchants Corp grew its position in Danaher by 7.8% in the 3rd quarter. First Merchants Corp now owns 38,679 shares of the conglomerate’s stock worth $9,596,000 after purchasing an additional 2,807 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of DHR stock traded down $0.23 during trading on Wednesday, reaching $248.53. 546,843 shares of the company’s stock traded hands, compared to its average volume of 2,719,792. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $184.08 billion, a P/E ratio of 42.18, a PEG ratio of 3.82 and a beta of 0.83. The firm’s 50-day moving average is $248.27 and its 200 day moving average is $233.19.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same quarter in the prior year, the firm earned $2.36 EPS. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. Equities research analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Transactions at Danaher

In related news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 103,984 shares of company stock valued at $25,997,094. Company insiders own 10.90% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of a number of recent analyst reports. TD Cowen upped their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Raymond James upped their price objective on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Bank of America upped their price objective on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. Citigroup upped their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, Barclays upped their price objective on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $267.31.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.